Advertisement

The Role of Interleukin-1 in Septic Shock

  • C. A. Dinarello
  • K. Aiura
  • J. A. Gelfand
Part of the Yearbook of Intensive Care and Emergency Medicine book series (YEARBOOK, volume 1992)

Abstract

Tumor necrosis factor (TNF) and Interleukin-1 (IL-1) are two polypeptide cytokines that possess a broad spectrum of biological properties. These cytokines share many of their various biological properties and, moreover, IL-1 and TNF often act in a synergistic fashion. For example, both IL-1 and TNF induce hemodynamic shock in experimental animals; the combined infusion of IL-1 and TNF produces tissue damage and metabolic derangements similar to those associated with injury and sepsis in humans [1–3]. Furthermore, serum TNF and IL-lβ levels are elevated in patients with gram-negative bacteremia, and correlate with the severity of the sepsis [2–6]. Although other mediators, such as arachidonic acid metabolites, platelet activating factor (PAF) and nitric oxide (NO) [7] also contribute to the pathophysiologic changes of gram-negative bacteremia, it is important to recognize that IL-1 and TNF induce cyclooxygenase, PAF, and nitric oxide synthase. Therefore, a working hypothesis for the role of these cytokines in sepsis is that they are produced during infection and trauma and they induce the subsequent effector molecules of the shock syndrome. This fundamental concept is illustrated in Fig. 1.

Keywords

Tumor Necrosis Factor Septic Shock Tumor Necrosis Factor Level Serum Tumor Necrosis Factor Septic Shock Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Movat HZ, Burrowes CE, Cybulsky MI, Dinarello CA (1987) Acute inflammation and a Shwartzman-like reaction induced by interleukin-1 and tumor necrosis factor. Synergistic action of the cytokines in the induction of inflammation and micro vascular injury. Am J Pathol 129:463–476 (published erratum appears in Am J Pathol 1988 Mar; 130 (3):642)PubMedGoogle Scholar
  2. 2.
    Okusawa S, Gelfand JA, Ikejima T, Connolly RJ, Dinarello CA (1988) Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxy-genase inhibition. J Clin Invest 81:1162–1172PubMedCrossRefGoogle Scholar
  3. 3.
    Tredget EE, Yu YM, Zhong S et al. (1988) Role of interleukin 1 and tumor necrosis factor on energy metabolism in rabbits. Am J Physiol 255:760–768Google Scholar
  4. 4.
    Cannon JG, van der Meer JWM, Kwiatkowski D et al. (1988) Interleukin-1 beta in human plasma: Optimization of blood collection, plasma extraction, and radioimmunoassay methods. Lymphokine Res 7:457–467PubMedGoogle Scholar
  5. 5.
    Cannon JG, Tompkins RG, Gelfand JA et al. (1990) Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Inf Dis 161:79–84CrossRefGoogle Scholar
  6. 6.
    Cannon JG, Gelfand JA, Tompkins RG, Hegarty MT, Burke JF, Dinarello CA (1990) Plasma IL-lβ and TNFα levels in humans following cutaneous injury. In: Dinarello CA et al. (eds) The Physiological and Pathological Effects of Cytokines, Wiley-Liss, New York pp 301–306Google Scholar
  7. 7.
    Moncada S, Palmer RMJ, Higgs EA (1991) Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharm Rev 43:109–142PubMedGoogle Scholar
  8. 8.
    Tracey K, Fong Y, Hesse DG et al. (1987) Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature 330:662–664PubMedCrossRefGoogle Scholar
  9. 9.
    Beutler B, Milsark IW, Cerami A (1985) Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229:869–871PubMedCrossRefGoogle Scholar
  10. 10.
    Alexander HR, Doherty GM, Buresh CM, Venzon DJ, Norton JA (1991) A recombinant human receptor antagonist to interleukin-1 improves survival after lethal endotoxemia in mice. J Exp Med 173:1029–1032PubMedCrossRefGoogle Scholar
  11. 11.
    Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson RC (1990) Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 348:550–552PubMedCrossRefGoogle Scholar
  12. 12.
    Wakabayashi G, Gelfand JA, Burke JF, Thompson RC, Dinarello CA (1991) A specific receptor antagonist for interleukin-1 prevents E. coli-induced shock. FASEB J 5:338–342PubMedGoogle Scholar
  13. 13.
    Vedder NB, Winn RK, Rice CL, Chi EY, Arfors KE, Harlan JM (1990) Inhibition of leukocyte adherence by anti-CD 18 monoclonal antibody attenuates reperfusion injury in the rabbit ear. Proc Natl Acad Sci USA 87:2643–2646PubMedCrossRefGoogle Scholar
  14. 14.
    Vedder NB, Winn RK, Rice CL, Chi EY, Arfors KE, Harlan JM (1988) A monoclonal antibody to the adherence-promoting leukocyte glycoprotein, CD18, reduces organ injury and improves survival from hemorrhagic shock and resuscitation in rabbits. J Clin Invest 81:939–944PubMedCrossRefGoogle Scholar
  15. 15.
    Pohlman TH, Stanness KA, Beatty PG, Ochs HD, Harlan JM (1986) An endothelial cell surface factor(s) induced by lipopolysaccharide, interleukin-1 and tumor necrosis factor increases neutrophil adherence by a CDwl8-dependent mechanism. J Immunol 136:4548–4553PubMedGoogle Scholar
  16. 16.
    Martin MA, Pfaller MA, Wenzel RP (1989) Coagulase-negative staphylococcal bacteremia. Ann Intern Med 110:9–16PubMedGoogle Scholar
  17. 17.
    Baddour LM, Christensen GD, Bisno AL (1987) Bacterial concentration correlations in experimental endocarditis caused by Staphylococcus epidermidis. J Clin Microbiol 25:207–210PubMedGoogle Scholar
  18. 18.
    Natanson C, Danner RL, Elin RJ et al. (1989) Role of endotoxemia in cardiovascular dysfunction and mortality. Escherichia coli and Staphylococcus aureus challenges in a canine model of human septic shock. J Clin Invest 83:243–251 (published erratum appears in J Clin Invest 1989 Mar; 83 (3): 1087)PubMedCrossRefGoogle Scholar
  19. 19.
    Wakabayashi G, Gelfand JA, Jung WK, Connolly RJ, Burke JF, Dinarello CA (1991) Staphylococcus epidermidis induces complement activation, TNF, IL-1, a shock-like state and tissue injury in rabbits without endotoxemia: Comparison to Escherichia coli. J Clin Invest 87:1925–1935PubMedCrossRefGoogle Scholar
  20. 20.
    Clark BD, Schindler R, Cominelli F, Shaw AR, Cannon JG, Dinarello CA (1991) Levels of IL-la and IL-lβ in rabbits during endotoxemia as measured by specific radioimmunoassays. J Appl Physiol 76:2412–2418Google Scholar
  21. 21.
    Fong Y, Tracey KJ, Moldawer LL et al. (1989) Antibodies to cachectin/tumor necrosis factor reduce interleukin lβ and interleukin 6 appearance during lethal bacteremia. J Exp Med 170:1627–1633PubMedCrossRefGoogle Scholar
  22. 22.
    Dinarello CA, Cannon JG, Wolff SM et al. (1986) Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med 163:1433–1450PubMedCrossRefGoogle Scholar
  23. 23.
    Dinarello CA (1991) Interleukin-1 and interleukin-1 antagonism. Blood 77:1627–1652PubMedGoogle Scholar
  24. 24.
    Shaldon S, Koch KM, Bingel M, Granolleras C, Deschodt G, Dinarello CA (1987) Modulation of plasma interleukin-1 and its circulating protein inhibitor (CPI) by hemodialysis and hemofiltration. Kidney Int (Abstract) 31:245Google Scholar
  25. 25.
    Arend WP, Joslin FG, Thompson RC, Hannum CH (1989) An IL-1 inhibitor from human monocytes. Production and characterization of biologic properties. J Immunol 143:1851–1858PubMedGoogle Scholar
  26. 26.
    Seckinger P, Dayer JM (1987) Interleukin-1 inhibitors. Ann Inst Pasteur/Immunol 138:461–516CrossRefGoogle Scholar
  27. 27.
    Barak V, Treves AJ, Yanai P, Halperin M, Braun S (1986) Interleukin-1 inhibitory activity secreted by a human myelomonocytic cell line (M20). Eur J Immunol 16:1449–1452PubMedCrossRefGoogle Scholar
  28. 28.
    Barak V, Peritt D, Treves AJ, Yanai P, Halperin M, Dinarello CA (1992) The specific IL-1 inhibitor from the M20 cell line is not related to the IL-1 receptor antagonist. Lymphokine Cytokine Res 10:437–442Google Scholar
  29. 29.
    Seckinger P, Lowenthal JW, Williamson K, Dayer JM, MacDonald HR (1987) A urine inhibitor of interleukin-1 activity that blocks ligand binding. J Immunol 139:1546–1549PubMedGoogle Scholar
  30. 30.
    Mazzei GJ, Seckinger PL, Dayer JM, Shaw AR (1990) Purification and characterization of a 26-kDa competitive inhibitor of interleukin 1. Eur J Immunol 20:683–689PubMedCrossRefGoogle Scholar
  31. 31.
    Dayer-Metroz MD, Wollheim CB, Seckinger P, Dayer JM (1989) A natural interleukin 1 (IL-1) inhibitor counteracts the inhibitory effect of IL-1 on insulin production in cultured rat pancreatic islets. J Autoimmun 2:163–171PubMedCrossRefGoogle Scholar
  32. 32.
    Balavoine JF, de Rochemonteix B, Williamson K, Seckinger P, Cruchaud A, Dayer JM (1986) Prostaglandin E2 and collagenase production by fibroblasts and synovial cells is regulated by urine-derived human interleukin 1 and inhibitor(s). J Clin Invest 78:1120–1124PubMedCrossRefGoogle Scholar
  33. 33.
    Engelmann H, Aderka D, Rubinstein M, Rotman D, Wallach D (1989) A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem 264:11974–11980PubMedGoogle Scholar
  34. 34.
    Eisenberg SP, Evans RJ, Arend WP et al. (1990) Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature (Lond) 343:341–346CrossRefGoogle Scholar
  35. 35.
    Carter DB, Deibel MRJ, Dunn CJ et al. (1990) Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein. Nature 344:633–638PubMedCrossRefGoogle Scholar
  36. 36.
    Dayoff MO, Barker WC, Hunt LT (1983) Establishing homologies in protein sequences. Meth Enzymol 91:524–545CrossRefGoogle Scholar
  37. 37.
    Haskill S, Martin M, Van Le L et al. (1991) cDNA cloning of a novel form of the interleukin-1 receptor antagonist associated with epithelium. Proc Natl Acad Sci USA 88:3681–3685PubMedCrossRefGoogle Scholar
  38. 38.
    Eisenberg S, Brewer MT, Verderber E, Heimdal P, Brandhuber BJ, Thompson RC (1992) IL-1 receptor antagonist is a member of the IL-1 gene family. Proc Natl Acad Sci USA (in press)Google Scholar
  39. 39.
    Dripps DJ, Brandhuber BJ, Thompson RC, Eisenberg SP (1991) Effect of IL-lra on IL-1 signal transduction. J Biol Chem 266:10331–10336PubMedGoogle Scholar
  40. 40.
    Granowitz EV, Clark BD, Mancilla J, Dinarello CA (1991) Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the type II interleukin-1 receptor. J Biol Chem 266:14147–14150PubMedGoogle Scholar
  41. 41.
    Rambaldi A, Torcia M, Bettoni S et al. (1990) Modulation of cell proliferation and cytokine production in acute myeloblastic leukemia by interleukin-1 receptor antagonist and lack of its expression by leukemic cells. Blood 76:114aGoogle Scholar
  42. 42.
    Arend WP, Welgus HG, Thompson RC, Eisenberg SP (1990) Biological properties of recombinant human monocyte-derived interleukin-1 receptor antagonist. J Clin Invest 85:1694–1697PubMedCrossRefGoogle Scholar
  43. 43.
    Granowitz EV, Clark BD, Vannier E, Callahan M, Dinarello CA (1992) IL-1 receptor antagonist blocks IL-1 induced cytokines by blocking the type II receptor on human monocytes. Blood (in press)Google Scholar
  44. 44.
    Mclntyre KW, Stepan GJ, Kolinsky DK et al. (1991) Interleukin-1 receptor antagonist blocks acute inflammatory responses to IL-1 and other agents in vivo. J Exp Med 173:931–939CrossRefGoogle Scholar
  45. 45.
    Fischer E, Marano MA, Zee KJ et al. (1991) IL-1 receptor blockade attenuates the hemody-namic and metabolic consequences of lethal E. coli septic shock. Am J Physiol 261:442–452Google Scholar
  46. 46.
    Mancilla J, Garcia P, Dinarello CA (1992) Comparison of IL-1 and IL-lra in protecting newborn rats from lethal Klebsiella infection. Cytokine (in press)Google Scholar
  47. 47.
    Aiura K, Gelfand JA, Wakabayashi G et al. (1992) Interleukin-1 receptor antagonist blocks staphylococcal induced shock in rabbits. Cytokine 3:498 (Abstract)Google Scholar
  48. 48.
    Dinarello CA, Ikejima T, Warner SJ et al. (1987) Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. J Immunol 139:1902–1910PubMedGoogle Scholar
  49. 49.
    Ikejima T, Ikusawa S, Ghezzi P, van der Meer JWM, Dinarello CA (1992) IL-1 induces TNF in human PBMC in vitro and a circulating TNF-like activity in rabbits. J Inf Dis 162:215–223CrossRefGoogle Scholar
  50. 50.
    Busse R, Mulsch A (1990) Induction of nitric oxide synthase by cytokines in vascular smooth muscle cells. FEBS (Lett) 275:87–90CrossRefGoogle Scholar
  51. 51.
    Beasley D, Schwartz JH, Brenner BM (1991) Interleukin-1 induces prolonged L-arginine-dependent cyclic guanosine monophosphate and nitrite production in rat vascular smooth muscle cells. J Clin Invest 87:602–608PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • C. A. Dinarello
  • K. Aiura
  • J. A. Gelfand

There are no affiliations available

Personalised recommendations